Navigation Links
Amylin Pharmaceuticals Reports 2008 Financial Results
Date:1/27/2009

008 2007 Revenues: Net product sales $184,922 $194,719 $765,342 $701,450 Revenues under collaborative agreements 17,569 27,319 74,767 79,547 Total revenues 202,491 222,038 840,109 780,997 Costs and expenses: Cost of goods sold 21,495 22,135 91,596 65,457 Selling, general and administrative 86,105 122,356 395,112 390,982 Research and development 67,022 83,888 293,095 276,600 Collaborative profit sharing 73,182 78,606 302,600 290,934 Restructuring 54,926 - 54,926 - Total costs and expenses 302,730 306,985 1,137,329 1,023,973 Operating loss (100,239) (84,947) (297,220) (242,976) Interest (expense) income, net (3,832) 8,006 (3,242) 31,840 Loss on impairment of equity method and available for sale investments - - (14,943) - Net loss $(104,071) $(76,941) $(315,405) $(211,136) Net loss per share - basic and diluted $(0.76) $(0.57) $(2.30) $(1.59) Shares used in computing net loss per share - basic and diluted 137,623 134,896 137,006 132,621

A reconciliation of reported GAAP net loss to non-GAAP operating loss excluding non-cash items, and other one-time items is provided in the table that follows (in thousands, unaudited):


                        Quarter ended December 31,  Year ended December 31,
                                2008       2007        2008        2007

    GAAP operating loss      $(100,239) $(84,947)   $(297,220) $(242,976)

    Stock-based compensation    1
'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Year-End Results
2. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
3. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
4. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
5. Lilly and Amylin Set Date and Time for Conference Call
6. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
7. Amylin Pharmaceuticals Reports First Quarter Financial Results
8. Amylin Pharmaceuticals Reports 2007 Financial Results
9. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
10. Amylin Pharmaceuticals to Present at Research & Development Day
11. Amylin Pharmaceuticals to Webcast Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... 2014 Secura Consultants, based in ... marketing organizations in the country focused on delivering ... marketplace. Secura Consultants is proud to offer complimentary ... Group, a leading global financial company. , Many ... the ownership interest comes the need for business ...
(Date:11/28/2014)... Alex Kramer HealthDay ... Getting kids involved in the kitchen, through cooking classes or ... foods, according to a recent review. Cooking programs and ... and behaviors, according to the new research. And, although the ... findings suggest that such programs might help children develop long-lasting ...
(Date:11/28/2014)... CA (PRWEB) November 28, 2014 ... online, reported during the hugely popular, 2014 MTV ... antismoking organization Truth launched ground-breaking celebrity centered television ... The MTV viewership figures were estimated by ... antismoking ads placed the spotlight on celebrities photographed ...
(Date:11/28/2014)... UniWigs.com, a leader in the wig industry, has announced ... next Monday. This promotion features: , > 400 ... to 70% off (no coupon code needed), > ... on orders over $49 , Visit http://www.uniwigs.com for more ... 28th to Dec. 1st and the first 100 shoppers each day ...
(Date:11/28/2014)... An inventor from Flint, Mich., wants to minimize the trouble ... while lying in a hospital bed, unable to get up ... Buddy provides a more ergonomic and convenient way for a ... need to leave the bed, which avoids hassle and strain, ... and producible in design variations, it's ideal for elderly and/or ...
Breaking Medicine News(10 mins):Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2
... today announced the,expansion of its proprietary pipeline, with ... orally-available small molecule compound,targeted for the treatment of ... inhibit major signalling pathways,involving Flt3 and CDK, which ... the most frequent genetic alterations,reported in acute myeloid ...
... NEWTOWN SQUARE, Pa., Nov. 27 In its ... homeopathy, Boiron,Laboratories disputes an editorial comment published in ... that its author has misinterpreted results of,clinical trials ... journal features an editorial by Ben Goldacre on,the ...
... say current labeling doesn,t reflect reports of bizarre behaviors ... (HealthDay News) -- A U.S. Food and Drug Administration ... Tamiflu (oseltamivir) should have a stronger warning label to ... who use the medication. , The FDA,s Pediatric Advisory ...
... ZMH ; SWX: ZMH) today announced that J. ... a member of the Board of Directors effective,November 30, ... John L.,McGoldrick, a current Board member, will serve as ... and Chief Executive Officer,of the Company from August 2001 ...
... Pronounced "mursa,",methicillin-resistant staphylococcus aureus (MRSA) is one of the ... it. It has,killed the elderly, babies, toddlers, teenagers and ... public schools., One of the most common places ... can start innocently, perhaps with a nick or cut. ...
... Rate..., CLEARWATER, Fla., Nov. 27 minSURG Corporation, ... it has certified over 600 surgeons in its TruFUSE ... in the basic technique at the,North American Spine Society ... believe that this milestone is a reasonable predictor that ...
Cached Medicine News:Health News:S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias 2Health News:Boiron Laboratories Disputes British Journal's Editorial on Homeopathy 2Health News:Boiron Laboratories Disputes British Journal's Editorial on Homeopathy 3Health News:FDA Panel Backs Tougher Warning for Tamiflu 2Health News:FDA Panel Backs Tougher Warning for Tamiflu 3Health News:Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman 2Health News:Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman 3Health News:New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Family's Feet 2Health News:Over 600 Surgeons Certified to use TruFUSE(R) to Treat Back Pain Sufferers 2
(Date:11/26/2014)... , Nov. 26, 2014   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... Ph.D., President and CEO of Regulus, will present a ... Jaffray Healthcare Conference at the New York Palace Hotel ... The presentation will be webcast at the time of ...
(Date:11/26/2014)... , Inc. (NASDAQ: BIOS ) announced today that ... at the Bank of America Merrill Lynch 2014 Leveraged Finance Conference ... , Wednesday, December 3, 2014 , , , , Time: ... Location: , , , Boca Raton Resort and Club, Florida , ... BioScrip, Inc. is a leading national provider of infusion and ...
(Date:11/26/2014)... , Nov. 26, 2014 The medical ... a rate of 4%, with world market revenues ... Information. MRI and other types of medical imaging ... treatment of numerous medical conditions in children and ... techniques. Kalorama,s report, Medical Imaging Markets , ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... Novelos Therapeutics, Inc. (OTCQX: NVLT) , a pharmaceutical ... of cancer, today announced that the University of ... institution, has successfully completed the first cohort in ... trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging ...
... 2012 HIGHLIGHTS :2012 Results (all ... Q1 2012 reported sales increased 5% to $665 million, a new ... Fine Chemicals ("SAFC") organic sales growth of 4% and 1%, respectively.  ... exchange rates reduced otherwise reportable sales by 2%. , ...
Cached Medicine Technology:Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 2Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 3Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 4Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 2Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 3Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 4Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 6Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 7Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 8Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 9Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 10Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 11Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 12Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 13
PremierEdge™ Stab Knives - 15°....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 2.0mm....
Medicine Products: